Amgen’s Prolia Complete Response submission: FDA classifies and sets PDUFA date Amgen Inc Levitra med dapoxetin . today announced that the U.S. With the Course 2 designation, the FDA set a corresponding Prescription Medication User Fee Work action date of July 25, 2010. Related StoriesElderly females should take more supplement D supplementation during the wintertime, suggests researchersNew protein supplement lowers cholesterol, october 2009 prevents osteoporosisDiet rich in soy protein and isoflavones can protect menopausal females from osteoporosisIn, the FDA’s Division of Reproductive and Urologic Products issued a Comprehensive Response Letter for the Biologic Permit Program for Prolia in the procedure and avoidance of postmenopausal osteoporosis.
This is the wholly corrupt scenario which has played out once again in federal court, this time with Amgen Inc., the world’s largest biotechnology company, which recently pleaded guilty to one misdemeanor count of marketing its blockbuster anemia drug Aranesp illegally. After generating vast amounts of dollars from Aranesp through the years – – the company sold $2.3 billion worth of the medication just in 2011 – – Amgen was found recently to possess illegally marketed the deadly medication for anemia due to cancer, a condition for which it had never been approved. According to reports, Amgen also pushed higher doses of Aranesp, and more frequent treatment schedules for the drug, in clear violation of the U.S.